Zimmer Biomet: Does Slow And Steady Still Win The Race?

Impact · against what's priced in

Zimmer Biomet shows strong operational momentum with rising margins and double-digit EPS growth. The combination of these fundamentals and a perceived valuation discount suggests an opportunity for price appreciation.

ZBH+0.60: No priced-in read yet
In context: The company delivered strong growth with net sales up 9.3% and adjusted EPS up 15.5%, while expanding adjusted gross margins to 73.0%.
Read from the article alone
Actual

Zimmer Biomet: Does Slow And Steady Still Win The Race?

earnings▲14%
cash flow▲1%
healthcare
valuation
ZBH
margins
medical devices
orthopedics

Zimmer Biomet: Does Slow And Steady Still Win The Race?

What matters in this story

Tractor Supply: 3 Key Takeaways for Long-Term Investors

Zimmer Biomet: Does Slow And Steady Still Win The Race?

What matters in this story

Tractor Supply: 3 Key Takeaways for Long-Term Investors

How each ticker is affected

Track these names every morning.

Xtract One Technologies Q4 Earnings Call Highlights

Procter & Gamble: 3 Key Takeaways for Long-Term Investors

Northern Trust: Efficiency Efforts Show Continued Progress (Rating Upgrade)

Newmont Q3 Earnings Call Highlights

Zimmer Biomet: Does Slow And Steady Still Win The Race?

What matters in this story

Next reads from the same story arc

Tractor Supply: 3 Key Takeaways for Long-Term Investors

Zimmer Biomet: Does Slow And Steady Still Win The Race?

What matters in this story

Next reads from the same story arc

Tractor Supply: 3 Key Takeaways for Long-Term Investors

How each ticker is affected

Track these names every morning.

Xtract One Technologies Q4 Earnings Call Highlights

Procter & Gamble: 3 Key Takeaways for Long-Term Investors

Northern Trust: Efficiency Efforts Show Continued Progress (Rating Upgrade)

Newmont Q3 Earnings Call Highlights